L-Carnitine is a modulator of the glucocorticoid receptor alpha

Annals of the New York Academy of Sciences

Volumn 1024, Issue , 2004, Pages 147-152

  Alesci, Salvatore ^a,b   De Martino, Massimo U ^b   Kino, Tomoshige ^b   Ilias, Ioannis ^b,c  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^b EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^c UNIVERSITY OF PATRAS   (Greece)

Author keywords

Cytokines; Glucocorticoid receptor alpha; Immunity

Indexed keywords

BETAMETHASONE; CARNITINE; GLUCOCORTICOID RECEPTOR; GLUCOCORTICOID RECEPTOR ALPHA; INTERLEUKIN 12; RECEPTOR SUBTYPE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

CACHEXIA; CONFERENCE PAPER; CYTOKINE RELEASE; DRUG RECEPTOR BINDING; GENE CONTROL; HUMAN; IMMUNOMODULATION; LOW DRUG DOSE; NEONATAL RESPIRATORY DISTRESS SYNDROME; NONHUMAN; PREMATURITY; PROTEIN INTAKE; PROTEIN SYNTHESIS INHIBITION; RECEPTOR INTRINSIC ACTIVITY; SEPTIC SHOCK; SURGICAL PATIENT; SURVIVAL RATE; TRANSCRIPTION INITIATION;

EID: 3042759103     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1196/annals.1321.012     Document Type: Conference Paper

References (35)

1. REBOUCHE, C.J. & H. SEIM. 1998. Carnitine metabolism and its regulation in microorganisms and mammals. Annu. Rev. Nutr. 18: 39-61.
2. BREMER, J. 1997. The role of carnitine in cell metabolism. In Carnitine Today. C. De Simone & G. Famularo, Eds.: 1-37. R.G. Landes Company. Austin, TX.
3. REBOUCHE, C.J. 1992. Carnitine function and requirements during the life cycle. FASEB J. 6: 3379-3386.
4. FURLONG, J.H. 1996. Acetyl-L-carnitine: metabolism and applications in clinical practice. Altern. Med. Rev. 1.
5. ARDUINI, A. et al. 1992. Role of carnitine and carnitine palmitoyltransferase as integral components of the pathway for membrane phospholipid fatty acid turnover in intact human erythrocytes. J. Biol. Chem. 267: 12673-12681.
6. FRITZ, I.B. & N.R. MARQUIS. 1965. The role of acylcarnitine esters and carnitine palmityltransferase in the transport of fatty acyl groups across mitochondrial membranes. Proc. Natl. Acad. Sci. USA 54: 1226-1233.
7. ANGELINI, C., S. LUCKE & F. CANTARUTTI. 1976. Carnitine deficiency of skeletal muscle: report of a treated case. Neurology 26: 633-637.
8. BOHLES, H. & W. LEHNERT. 1984. The effect of intravenous L-carnitine on propionic acid excretion in acute propionic acidaemia. Eur. J. Pediatr. 143: 61-63.
9. ROE, C.R. et al. 1984. L-Carnitine enhances excretion of propionyl coenzyme A as propionylcarnitine in propionic acidemia. J. Clin. Invest. 73: 1785-1788.
10. WALTER, P. & A.O. SCHAFFHAUSER 2000. L-Carnitine, a "vitamin-like substance" for functional food. Proceedings of the Symposium on L-Carnitine, April 28-May 1, 2000, Zermatt, Switzerland. Ann. Nutr. Metab. 44: 75-96.
11. BORUM, P.R. 2000. Supplements: questions to ask to reduce confusion. Am. J. Clin. Nutr. 72: 538S-40S.
12. PRATT, W.B. 1992. Control of steroid receptor function and cytoplasmic-nuclear transport by heat shock proteins. Bioessays 14: 841-848.
13. PRATT, W.B., U. GEHRING & D.O. TOFT. 1996. Molecular chaperoning of steroid hormone receptors. Experientia Suppl. 77: 79-95.
14. BAMBERGER, C.M., H.M. SCHULTE & G.P. CHROUSOS. 1996. Molecular determinants of glucocorticoid receptor function and tissue sensitivity to glucocorticoids. Endocr. Rev. 17: 245-261.
15. LEFEBVRE, P. et al. 1988. Association of the glucocorticoid receptor binding subunit with the 90K nonsteroid-binding component is stabilized by both steroidal and non-steroidal antiglucocorticoids in intact cells. Biochemistry 27: 9186-9194.
16. DAO-PHAN, H.P., P. FORMSTECHER & P. LEFEBVRE. 1997. Disruption of the glucocorticoid receptor assembly with heat shock protein 90 by a peptidic antiglucocorticoid. Mol. Endocrinol. 11: 962-972.
17. BAMBERGER, C.M. et al. 1997. Inhibition of mineralocorticoid and glucocorticoid receptor function by the heat shock protein 90-binding agent geldanamycin. Mol. Cell Endocrinol. 131: 233-240.
18. WINTER, B.K., G. FISKUM & L.L. GALLO. 1995. Effects of L-carnitine on serum triglyceride and cytokine levels in rat models of cachexia and septic shock. Br. J. Cancer 72: 1173-1179.
19. RUGGIERO, V. et al. 1993. LPS-induced serum TNF production and lethality in mice: effect of L-carnitine and some acyl-derivatives. Med. Inflamm. 2: S43-S50.
20. FATTOROSSI, A. et al. 1993. Regulation of normal human polymorphonuclear leucocytes by carnitine. Med. Inflamm. 2: S37-S41.
21. DELOGU, G. et al. 1993. Anaesthetics modulate tumour necrosis factor alpha: effects of L-carnitine supplementation in surgical patients. Preliminary results. Med. Inflamm. 2: S33-S36.
22. DE SIMONE, C. et al. 1993. High dose L-carnitine improves immunologic and metabolic parameters in AIDS patients. Immunopharmacol. Immunotoxicol. 15: 1-12.
23. LOHNINGER, A. et al. 1996. Prenatal effects of betamethasone-L-carnitine combinations on fetal rat lung. J. Perinat. Med. 24: 591-599.
24. LOHNINGER, A. et al. 1984. Comparison of the effects of betamethasone and L-carnitine on dipalmitoylphosphatidylcholine content and phosphatidylcholine species composition in fetal rat lungs. Pediatr. Res. 18: 1246-1252.
25. LOHNINGER, A. et al. 1986. Studies on the effects of betamethasone, L-carnitine, and betamethasone-L-carnitine combinations on the dipalmitoyl phosphatidylcholine content and phosphatidylcholine species composition in foetal rat lungs. J. Clin. Chem. Clin. Biochem. 24: 361-368.
26. SALZER, H. et al. 1983. 1st report: alternatives to cortisone therapy. 1st clinical experiences with a carnitine-betamethasone combination for the stimulation of fetal lung maturity. Wien Klin. Wochenschr. 95: 724-728.
27. KURZ, C. et al. 1993. L-Carnitine-betamethasone combination therapy versus betamethasone therapy alone in prevention of respiratory distress syndrome. Z. Geburtshilfe Perinatol. 197: 215-219.
28. ALESCI, S. et al. 2003. L-carnitine: a nutritional modulator of glucocorticoid receptor functions. FASEB J. 17: 1553-1555.
29. FEARON, D.T. & R.M. LOCKSLEY. 1996. The instructive role of innate immunity in the acquired immune response. Science 272: 50-53.
30. TRINCHIERI, G. 1995. Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Annu. Rev. Immunol. 13: 251-276.
31. ELENKOV, I.J. et al. 1996. Modulatory effects of glucocorticoids and catecholamines on human interleukin-12 and interleukin-10 production: clinical implications. Proc. Assoc. Am. Physicians 108: 374-381.
32. FOSTER, S.J. et al. 1993. Production of TNF alpha by LPS-stimulated murine, rat and human blood and its pharmacological modulation. Agents Actions 38: C77-79.
33. KATAKAMI, N., Y. NAKAO & T. FUJITA. 1991. Suppressive effect of 1,25(OH)2D3 and glucocorticoids on production of tumor necrosis factor alpha by human peripheral blood adherent cells. Kobe J. Med. Sci. 37: 179-188.
34. CHIU, K.M. et al. 1999. Carnitine and dehydroepiandrosterone sulfate induce protein synthesis in porcine primary osteoblast-like cells. Calcif. Tissue Int. 64: 527-533.
35. BENVENGA, S. et al. 2001. Usefulness of L-carnitine, a naturally occurring peripheral antagonist of thyroid hormone action, in iatrogenic hyperthyroidism: a randomized, double-blind, placebo-controlled clinical trial. J. Clin. Endocrinol. Metab. 86: 3579-3594.